Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

PURPOSE: Primary prophylaxis, using factor VIII replacement, is the recognized standard of care for severe hemophilia A. Recombinant factor VIII-Fc fusion protein (rFVIIIFc) and emicizumab, a humanized, bispecific antibody, are approved for routine prophylaxis of bleeding episodes in severe hemophil...

Descripción completa

Detalles Bibliográficos
Autores principales: Klamroth, Robert, Wojciechowski, Piotr, Aballéa, Samuel, Diamand, Françoise, Hakimi, Zalmai, Nazir, Jameel, Abad-Franch, Lydia, Lethagen, Stefan, Santagostino, Elena, Tarantino, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921628/
https://www.ncbi.nlm.nih.gov/pubmed/33664606
http://dx.doi.org/10.2147/JBM.S288283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921628/
https://www.ncbi.nlm.nih.gov/pubmed/33664606
http://dx.doi.org/10.2147/JBM.S288283

Ejemplares similares